乳腺癌HER-2基因扩增检测方法对比及与临床病理特征的关系  

Comparison of the method to detect the HER-2 gene amplification condition in breast carcinoma and its relationship with clinicopathological characteristics

作　　者：魏静远 王艳茹[1] 段瑞[1] 范学娇 许春伟[2] 吴继华[1] 

机构地区：[1]解放军306医院病理科,北京100101 [2]军事医学科学院附属医院病理科,北京100071

出　　处：《贵州医药》2017年第11期1126-1128,共3页Guizhou Medical Journal

摘　　要：目的比较乳腺癌组织中人表皮生长因子受体2(HER-2)基因扩增及蛋白表达符合率,探讨HER-2基因扩增与乳腺癌患者临床病理特征的相关性。方法采用免疫组织化学(IHC)和荧光原位杂交(FISH)检测121例乳腺癌患者的HER-2基因扩增及表达状态,对二者的符合率进行分析,并对HER-2基因扩增与患者年龄、乳腺癌组织学类型、转移、肿瘤增殖活性、激素受体等相关性进行分析。结果 121例乳腺癌患者中,HER-2基因扩增37例(37/121,30.6%),其中IHC法检测乳腺癌患者HER-2(+++)4例中全部有基因扩增(4/4,100%),HER-2(++)55例中有27例(27/55,49.1%)基因扩增,HER-2(+)51例中有6例(11.8%)基因扩增,HER-2(-)11例中均无基因扩增。107例浸润性导管癌中有32例(32/107,30.0%)基因扩增,5例浸润性小叶癌中有1例(1/5,20%)基因扩增,9例其他肿瘤类型中有4例(4/9,44.4%)基因扩增。不同肿瘤类型间HER-2基因扩增阳性率差异显著(P<0.05)。雌激素孕激素受体与HER-2基因扩增差异显著(P<0.05),且呈负相关。HER-2基因扩增与年龄、淋巴结转移、肿瘤增殖活性差异不显著,无统计学意义。结论IHC检测HER-2(+++)、HER-2(-)的病例与FISH检测结果保持一致,HER-2(+)病例可选择性做FISH进行确认,对于HER-2(++)病例均应常规进行FISH检测,以便更加准确地为患者制定治疗方案。HER-2基因扩增与乳腺癌类型、雌激素、孕激素水平相关,与患者年龄、淋巴结转移、肿瘤增殖活性无关。Objective To compare the coincidence rate between gene amplification and the protein expression of epidermal growth factor receptor 2 （HER-2）in breast carcinoma, and to explore the relationship between HER-2 gene amplification and clinical pathological characteristics of breast carcinoma patients. Methods HER-2 gene amplification and expression in 121 cases of breast carcinoma patients was tested by using Immunohistochemistry（IHC）and Fluorescence in situ hybridization（FISH）. The consistency of the two methods and the correlation between HER-2 gene amplification and patients＇ age, histological type ,metastasis, tumor proliferation activity and hormone receptor were analyzed. Results Among 121 cases of breast carcinoma patients,there were 37 cases with HER-2 gene amplification （30.6 % ）. And the 4 cases of the patients with results of HER-2 （＋ ＋ ＋ ）all had gene amplification（ 100 % ）. Among the 55 cases of patients with results of HER-2（＋＋）,there were 27 cases with gene amplification（49.1%）. And 6 out of 51 cases HER-2 （ ＋ ） had HER-2 gene amplification（ 11.8 % ）. The HER-2 （ - ） cases （ 11 ） had no gene amplification. By analyzing HER-2 gene amplification in different histological types, the conclusion as follows that 32 of 107 cases of invasive ductal carcinoma had HER-2 gene amplification（30.0 % ）, 1 of 5 cases of invasive lobular carcinoma had HER-2 gene amplification（20 %）and 4 of 9 cases of other histological types had gene amplification（44.4%）. There were statistical significantly differences of positive rate of HER-2 gene amplification between different histological types and ER PR（P〈0.05）. There were no statistical significantly differences of HER gene amplification between age,lymph node metastasis and tumor proliferation activity（P〉0.05）. Conclusion The results of IHC HER-2 （＋ ＋ ＋/-） is consistent with the results of FISH. In some cases, HER-2 gene amplification of HER-2 （＋）could not be confirmed,and FIS

关 键 词：乳腺癌 人表皮生长因子受体HER-2 免疫组织化学 荧光原位杂交 

分 类 号：R737.5[医药卫生—肿瘤]